880 related articles for article (PubMed ID: 23433601)
1. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
[TBL] [Abstract][Full Text] [Related]
2. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
Zambrowicz B; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Boehm KA; Ruff D; Powell D; Sands A
Clin Ther; 2013 Aug; 35(8):1162-1173.e8. PubMed ID: 23911260
[TBL] [Abstract][Full Text] [Related]
3. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.
Powell DR; Smith M; Greer J; Harris A; Zhao S; DaCosta C; Mseeh F; Shadoan MK; Sands A; Zambrowicz B; Ding ZM
J Pharmacol Exp Ther; 2013 May; 345(2):250-9. PubMed ID: 23487174
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
5. Effect of LX4211 on glucose homeostasis and body composition in preclinical models.
Powell DR; DaCosta CM; Smith M; Doree D; Harris A; Buhring L; Heydorn W; Nouraldeen A; Xiong W; Yalamanchili P; Mseeh F; Wilson A; Shadoan M; Zambrowicz B; Ding ZM
J Pharmacol Exp Ther; 2014 Aug; 350(2):232-42. PubMed ID: 24849925
[TBL] [Abstract][Full Text] [Related]
6. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
7. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
8. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
[TBL] [Abstract][Full Text] [Related]
9. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
[TBL] [Abstract][Full Text] [Related]
10. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose.
Vardarli I; Arndt E; Deacon CF; Holst JJ; Nauck MA
Diabetes; 2014 Feb; 63(2):663-74. PubMed ID: 24186866
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
12. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
13. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
Choy M; Lam S
Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
[TBL] [Abstract][Full Text] [Related]
14. The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study.
Stevens JE; Horowitz M; Deacon CF; Nauck M; Rayner CK; Jones KL
Aliment Pharmacol Ther; 2012 Aug; 36(4):379-90. PubMed ID: 22738299
[TBL] [Abstract][Full Text] [Related]
15. Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.
Wu T; Ma J; Bound MJ; Checklin H; Deacon CF; Jones KL; Horowitz M; Rayner CK
Diabetes; 2014 Aug; 63(8):2776-87. PubMed ID: 24647737
[TBL] [Abstract][Full Text] [Related]
16. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Lapuerta P; Zambrowicz B; Strumph P; Sands A
Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
[TBL] [Abstract][Full Text] [Related]
17. LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion.
Zambrowicz B; Lapuerta P; Strumph P; Banks P; Wilson A; Ogbaa I; Sands A; Powell D
Clin Ther; 2015 Jan; 37(1):71-82.e12. PubMed ID: 25529979
[TBL] [Abstract][Full Text] [Related]
18. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
[TBL] [Abstract][Full Text] [Related]
19. The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model.
Shang Q; Liu MK; Saumoy M; Holst JJ; Salen G; Xu G
Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G815-23. PubMed ID: 22281473
[TBL] [Abstract][Full Text] [Related]
20. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
